|Type||Public (Nasdaq: )|
See more complete products listing.
NWBO's stated goals stress product quality and purity, innovation, and efficient production.
The DCVax technology upon which NWBO's therapies rely involves injecting cancer patients with dendritic cells, which contain high levels of the same antigens found in tumor cells. The immune system, alerted by these antigens, attacks the cancer as well as the injected cells.
DCVax-L is now in Phase 3 trials in USA & Europe. DCVax-Direct is a therapy to treat inoperable solid tumors.
Footnotes and references
|This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.|